Home » Topics » Regulatory » EMA

EMA
RSS

The EMA validates PTC Therapeutics' MAA for ataluren

Dec. 10, 2012

FDA approves Cometriq, EMA accepts MAA

Nov. 30, 2012

EMA recommends granting orphan status to Aspireo's somatoprim

Nov. 26, 2012

EMA to begin formal review of macitentan MAA

Nov. 22, 2012

Zytiga receives positive CHMP recommendation for castration-resistant prostate cancer

Nov. 20, 2012

CHMP recommends Exjade approval for non-transfusion-dependent thalassemia syndromes

Nov. 20, 2012

EMA committee recommends approval of lixisenatide

Nov. 19, 2012

CHMP recommends approval of Novartis's meningococcal group B vaccine

Nov. 19, 2012

Zaltrap receives positive CHMP opinion for metastatic colorectal cancer

Nov. 19, 2012

European Commission denies marketing authorization for taliglucerase alfa

Nov. 5, 2012

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...